Source: Annual Congress 2008 - Pleural diseases and interventions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Tas, O. Okutan, O. M. Ipcioglu, F. Ciftci, Z. Kartaloglu (Istanbul, Turkey). The role of vascular endothelial growth factor in tuberculous and parapneumonic pleural effusions. Eur Respir J 2008; 32: Suppl. 52, 1667

Member's Comments

No comment yet.

Related content which might interest you: Vascular endothelial growth factor (VEGF) in malignant and tuberculous pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Profibrotic implication of platelet-activating factor in tuberculous pleural effusion Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 The diagnostic value of vascular endothelial growth factor in pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 246s Year: 2004 Interelukin-17A is elevated in parapneumonic pleural effusions and is associated with neutrophils and VEGF Source: Eur Respir J 2006; 28: Suppl. 50, 551s Year: 2006 Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura Year: 2012 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 Role of C-reactive protein in discriminating complicated and uncomplicated parapneumonic effusion from malignant and tuberculous pleural effusion Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status Year: 2021 Vascular endothelial growth factor in pleural effusions of different origin Source: Eur Respir J 2005; 25: 600-604 Year: 2005 Prognostic features of residual pleural thickening after parapneumonic pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 605s Year: 2002 Osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Host-derived osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Can VEGF be used in differential diagnosis of pleural effusions? Source: Eur Respir J 2007; 30: Suppl. 51, 565s Year: 2007 Empyema and parapneumonic pleural effusion. Prognostic factors about 109 patients Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Pleural-fluid myeloperoxidase in complicated and noncomplicated parapneumonic pleural effusions Source: Eur Respir J 2002; 19: 320-325 Year: 2002 Prognostic features of residual pleural thickening in parapneumonic pleural effusions Source: Eur Respir J 2003; 21: 952-955 Year: 2003 The role of aquaporin-1 in the formation of pleural effusion Source: Eur Respir J 2005; 26: Suppl. 49, 553s Year: 2005 C-reactive protein in differentiation between tuberculous and malignant pleural effusions Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Pleural fluid IL-6 levels in the identification of the complicated parapneumonic pleural effusion Source: Annual Congress 2008 - Pleural effusion Year: 2008 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Is pleural VEGF a useful parameter? Source: Annual Congress 2007 - Pleural malignancy Year: 2007